Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline

See more here:
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.